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p19ARF Deficiency Reduces Macrophage
and Vascular Smooth Muscle Cell
Apoptosis and Aggravates Atherosclerosis
Herminia Gonza´lez-Navarro, PHD,* Yafa Naim Abu Nabah, PHD,* Ángela Vinué, BSC,*
Marı´a J. Andrés-Manzano, BSC,† Manuel Collado, PHD,‡ Manuel Serrano, PHD,‡
Vicente Andrés, PHD*†
Valencia and Madrid, Spain
Objectives The goal of this study was to investigate the role in atherosclerosis of the tumor suppressor protein ARF (human
p14ARF, mouse p19ARF) encoded by the CDKN2A gene.
Background Atherosclerosis is characterized by excessive proliferation and apoptosis, 2 cellular processes regulated by
CDKN2A. Although recent genome-wide association studies have linked atherosclerotic diseases to a genomic
region in human chromosome 9p21 near the CDKN2A locus, the mechanisms underlying this gene–disease as-
sociation remain undefined, and no causal link has been established between CDKN2A and atherosclerosis.
Methods Atherosclerosis-prone apolipoprotein E (apoE)-null and doubly deficient apoE-p19ARF mice were fed an athero-
genic diet and sacrificed to quantify atherosclerosis burden in whole-mounted aortas and in aortic cross-
sections. Proliferation and apoptosis were investigated in atherosclerotic lesions and in primary cultures of mac-
rophages and vascular smooth muscle cells obtained from both groups of mice.
Results Genetic disruption of p19ARF in apoE-null mice augments aortic atherosclerosis without affecting body weight,
plasma lipoproteins, or plaque’s proliferative activity. Notably, p19ARF deficiency significantly attenuates apopto-
sis both in atherosclerotic lesions and in cultured macrophages and vascular smooth muscle cells, 2 major cellu-
lar constituents of atheromatous plaques.
Conclusions Our findings establish a direct link between p19ARF, plaque apoptosis, and atherosclerosis, and suggest that hu-
man genetic variants associated to diminished CDKN2A expression may accelerate atherosclerosis by limiting
plaque apoptosis. (J Am Coll Cardiol 2010;55:2258–68) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.026m
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rtherosclerosis and coronary artery disease are the major cause
f mortality in Western societies. Atheroma development is a
hronic inflammatory process resulting from the interaction
etween modified lipoproteins, circulating leukocytes, and
lements of the arterial wall, including endothelial cells,
onocyte-derived macrophages, T cells, and vascular smooth
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010, accepted January 18, 2010.uscle cells (VSMCs) (1–4). The disease in humans and
xperimental animals is characterized by excessive cell prolif-
ration and apoptosis within the atheroma, 2 processes that
ffect mainly macrophages and VSMCs (5–9).
See page 2269
The tumor suppressors p15INK4b, p16INK4a, and ARF (p14ARF
n humans, p19ARF in mice) constitute one of the main
ntioncogenic defenses of mammalian organisms (10,11). The
DKN2A gene encodes the nonhomologous proteins
16INK4a and ARF, and the adjacent CDKN2B gene encodes
15INK4b. p16INK4a and p15INK4b cause growth arrest through
he inhibition of CDK4 and CDK6 activity and the ensuing
ccumulation of the hypophosphorylated form of the retino-
lastoma protein (12,13). ARF appears to play a more relevant
ole as a proapoptotic factor via inhibition of MDM2, a
biquitin ligase that destabilizes the tumor suppressor p53
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16INK4a and ARF may limit the regenerative potential of
tem cell pools in certain tissues (14–17).
By analyzing a small cohort that included 316 patients and
34 controls, Rodriguez et al. (18) reported lack of association
etween the risk of suffering myocardial infarction and the single
ucleotide polymorphisms (SNPs) rs3731238, rs3814960, and
s3731249 located in the CDKN2A gene. However, recent inde-
endent genome-wide association studies that included thousands
f controls and patients have identified a number of SNPs located
n a region of chromosome 9p21 very close to the CDKN2A
ene that are linked to high risk of atherosclerosis and
ssociated cardiovascular disease, including coronary artery
isease, myocardial infarction, and ischemic stroke (19–25).
nterestingly, Liu et al. (26) recently reported reduced expres-
ion of the CDKN2A transcripts p16INK4a, p14ARF, and the
oncoding RNA named ANRIL (antisense noncoding RNA
n the INK4 locus) in purified peripheral blood T cells of
ndividuals carrying in homozygosis the atherosclerosis risk G
llele of rs10757278. These studies suggest a molecular mech-
nism by which diminished expression of CDKN2A transcripts
ssociated to genetic variants in this locus increases the risk of
therosclerosis. However, a causal link between reduced
DKN2A expression and atherosclerosis has not been estab-
ished. Here, we investigated the consequences of inactivating
19ARF on atheroma development in the widely used apoli-
oprotein E–null (apoE/) mouse model of atherosclerosis.
ethods
ice, diets, and metabolic measurements. Care of ani-
als was in accordance with institutional guidelines and
egulations. Mice deficient for p19ARF (p19/) (27) were
ackcrossed for more than 8 generations in a C57BL/6J
ackground and then were crossed with apoE/ mice
C57BL/6J, Charles River, Wilmington, Massachusetts) to
enerate doubly deficient apoE/p19/ mice. Informa-
ion for genotyping of mice is provided in the Online
ppendix. After weaning, mice were maintained on a
ow-fat standard diet (2.8% fat; Panlab, Barcelona, Spain).
t 2 months of age, male apoE/ and apoE/p19/
ittermates were placed for different periods of time on an
therogenic diet (10.8% total fat, 0.75% cholesterol without
odium cholate, S4892-E010, Ssniff, Soest, Germany).
Plasma lipid levels in mice fasted overnight were mea-
ured using enzymatic procedures (WAKO, St. Louis,
issouri). High-density lipoprotein cholesterol (HDL-C)
as determined after precipitation of the apolipoprotein
-containing lipoproteins with dextran sulphate/MgCl2
Sigma, St. Louis, Missouri) as previously described (28).
uantification of atherosclerosis burden. Fat-fed mice
ere sacrificed and the aorta was removed after in situ
erfusion with PBS followed by 4% paraformaldehyde/PBS.
ixation was continued overnight. An operator who was
linded to genotype quantified the extent of atherosclerosis
y computer-assisted morphometric analysis (SigmaScan sro5, Aspire Software Interna-
ional, Ashburn, Virginia) of both
hole-mounted aorta stained with
il Red O (0.2% Oil Red O in
0% MeOH) (Sigma) and
ematoxylin/eosin-stained cross-
ections of paraffin-embedded
ortic root and ascending aorta as
reviously described (29).
mmunohistochemical analysis of
therosclerotic plaques. Immuno-
istopathological examination of
theromas performed by a re-
earcher blinded to genotype in-
luded the quantification of the
ontent of macrophages, VSMCs,
nd collagen (Masson’s trichrome
tain). VSMCs were identified
ith mouse anti-smooth muscle
SM) -actin monoclonal alkaline
hosphatase-conjugated antibody
1/20 dilution, clone 1A4) and Fast Red substrate (both from
igma). Macrophages were detected with a rat anti-Mac3
onoclonal antibody (1/200 dilution, clone M3/84, sc-19991,
anta Cruz Biotechnology, Santa Cruz, California), followed
y biotin-conjugated goat anti-rat secondary antibody (1/300
ilution, sc-2041, Santa Cruz Biotechnology), streptavidin-
RP (Ref. TS-060-HR, Lab Vision Corporation, Fre-
ont, California), and DAB substrate (BUF021A, AbD
erotec). Specimens were counterstained with hematoxylin.
Cell proliferation in atheromatous lesions from the aortic
alves and ascending aorta was estimated by immunostain-
ng with a pre-diluted rabbit anti-Ki67 monoclonal anti-
ody (Clone SP6, MD, Vector Laboratories, Burlingame,
alifornia), followed by incubation with a biotinylated
nti-rabbit secondary antibody (1/300 dilution, Ref. R0919,
ector Laboratories), streptavidin-HRP, and DAB
ubstrate.
Apoptosis in the aortic valve region was determined using
he TUNEL method as recommended by the manufacturer
ApopTag Peroxidase In Situ Apoptosis Detection Kit, Ref.
7100, Millipore Ibérica, Madrid, Spain). Immunocom-
lexes were detected with DAB substrate and counter-
tained with hematoxylin.
For double TUNEL-Mac3 and TUNEL-SM -actin
taining, TUNEL-stained slides were incubated with the
nti-Mac3 or anti-SM -actin antibodies, respectively (see
he previous text). The TUNEL-Mac3–stained specimens
ere incubated with biotin-conjugated goat anti-rat second-
ry antibody and streptavidin-alkaline phosphatase (1/50,
ef. 551008, BD Pharmingen, Madrid, Spain). In both
ases, immunocomplexes were detected with Fast Red
ubstrate (Sigma). Apoptotic macrophages and VSMCs
ere quantified as the percentage of TUNEL-positive cells
hat were also Mac3-positive or SM -actin–positive, re-
Abbreviations
and Acronyms
apoE  apolipoprotein E
BMDM  bone marrow-
derived macrophage
BrdU  bromodeoxyuridine
GSNO  S-nitrosoglutathione
LDL  low-density
lipoprotein
SM  smooth muscle
SNP  single nucleotide
polymorphism
TUNEL  terminal
deoxynucleotidyl
transferase dUTP nick-end
labeling
UV  ultraviolet light
VSMC  vascular smooth
muscle cellpectively. Images were captured with an Olympus
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spaña, Barcelona, Spain) mounted on an Axiolab ste-
eomicroscope (Carl Zeiss Meditec Iberia, Tres Cantos,
pain).
rimary cell cultures. Bone marrow-derived macrophages
BMDMs) were obtained from femoral bone marrow sus-
ensions plated at 3  106 cells/ml and differentiated for 7
ays in the presence of DMEM/10% FBS/10% macrophage
olony-stimulating factor (29). VSMC cultures were pre-
ared from thoracic aorta harvested from 3- to 5-month-old
nimals after 2 digestions in HBSS/Fungizone medium as
reviously described (29). Briefly, the aorta was first di-
ested with type II collagenase (175 U/ml, Worthington
iochemical Corp., Lakewood, New Jersey) to remove the
dventitia, and cell suspensions were obtained after a second
igestion with type II collagenase (175 mg/ml) (Worthing-
on) and type I Elastase (0.5 mg/ml) (Sigma). Cultures were
aintained at 37°C in a humidified 5% CO2 atmosphere.
SMCs were cultured in 20% FBS/DMEM/Fungizone
nd used until passage 10. The identity of the cells as
SMCs was confirmed by immunohistochemistry using
nti-SM -actin antibody (see the previous text).
n vitro cell proliferation. For proliferation studies, asyn-
hronously growing cultures of BMDMs were plated on
lass coverslips and incubated with 50 M bromodeoxyuri-
ine (BrdU) for 18 h. Cells were fixed for 30 min with 4%
araformaldehyde/PBS, permeabilized with 0.5% Triton
-100/2 M HCl, washed extensively with sodium borate
uffer (pH 8.5), and incubated with a mouse monoclonal
nti-BrdU antibody (1 h, room temperature, 1/200, clone
oBu-1, 11-286-c100, Exbio, Vestec, Czech Republic)
ollowed by an Alexa Fluor 488–conjugated goat anti-
ouse secondary antibody (1 h, room temperature, 1/500,
11029, Invitrogen, Carlsbad, California). Cell nuclei were
tained with Hoechst (1/500, 15 min, Sigma) for total cell
ount, and coverslips were mounted with slow-fade gold
ntifade reagent (S36936, Invitrogen) and analyzed by
uorescent microscopy. For VSMC FACS-based cell-cycle
nalysis, cells were synchronized in G0/G1 by 72-h serum-
eprivation (DMEM–0.1% FBS) and then restimulated
ith DMEM–20% FBS for different times. Cells were
rypsinized, washed with PBS, collected by centrifugation (5
in, 600g), fixed with 80% ethanol (1 h, 20°C), and
abeled with propidium iodide (50 g/ml, 30 min at room
emperature, containing 0.25 mg/ml RNase A). Cells were
nalyzed using a BD FACSCanto Flow cytometer (BD
iosciences) and DNA histograms were fitted into cell-
ycle distributions using the ModFit 3.0 software (Verity
oftware House, Topsham, Maine).
n vitro apoptosis. Cells were either irradiated with ultra-
iolet (UV) light (BMDM: 80 J/m2, VSMC: 120 J/m2) and
ultured an additional 24 h (BMDM) or 48 h (VSMC),
ncubated with free-cholesterol at 100 g/ml (BMDM:
4 h, VSMC: 48 h), or incubated with the nitric oxide
onor S-nitrosoglutathione (GSNO) (2 mM, Sigma)
BMDM: 24 h, VSMC: 48 h). For apoptosis analysis by pow cytometry, control and treated cells were collected by
rypsinization at 37°C, rinsed with PBS, collected at low
peed (700g, 5 min), and fixed for propidium iodide staining
s described earlier or for cleaved caspase-3 staining as
ollows. Cells were fixed 10 min at 37°C with 2% to 4%
araformaldehyde/PBS, permeabilized with prechilled 90%
ethanol (30 min on ice), and stained with a rabbit polyclonal
nti-cleaved caspase 3 (Asp175) antibody (1/200, Cell Signal-
ng Technology, Beverly, Massachusetts), followed by Alexa
luor 488-conjugated goat anti-rabbit IgG secondary antibody
F[ab=]2 fragment, 1 h at room temperature, 1/500, A-11070,
nvitrogen). Apoptotic cells were identified as the sub-G0 peak
ubpopulation after propidium iodide staining or as cleaved
aspase-3 (Asp175)-positive cells.
tatistical analysis. Data are presented as mean  SEM.
ifferences among groups were evaluated by the Student t
est, 2-way ANOVA with Fisher post hoc test (Statview,
AS institute, Cary, North Carolina) or nonparametric
ann-Whitney U test (GraphPad Prism Software, La Jolla,
alifornia). Outliers identified by Grubb’s test were not
onsidered for quantification.
esults
enetic disruption of p19ARF accelerates atherosclerosis
n apoE/ mice. To assess the role of p19ARF on athero-
clerosis, 2-month-old apoE/ mice and apoE/p19/
iblings were fed a high-fat cholesterol-rich diet for 9 weeks.
s shown in Figure 1A, body weight increased in both
roups of mice during the period of fat feeding, reaching
tatistically significant differences in apoE/ mice at 4 and
weeks versus 0 and 1 week, and in apoE/p19/ mice
t 4 weeks versus 0 week and at 9 weeks versus 0, 1, and 4
eeks (see p values in Fig. 1A). No differences were
bserved between apoE/ and apoE/p19/ mice at any
ime point analyzed. Likewise, circulating levels of total
holesterol and triacylglycerides increased significantly in
oth groups of fat-fed mice compared with their pre-diet
alues (Fig. 1B), but no differences were seen when com-
aring apoE/ and apoE/p19/ mice. Thus, body
eight and circulating lipids in control and fat-fed apoE-
ull mice remained unaffected by genetic disruption of
19ARF. We next quantified atherosclerosis burden by
lanimetric analysis of whole-mounted oil Red-O–stained
ortic arch and thoracic aorta and by analyzing cross-
ections through the aortic root and ascending aorta. Com-
ared with apoE/ counterparts, apoE/p19/ mice
xhibited a significant increase in atheroma size in the aortic
rch (1.5-fold, p  0.012) (Fig. 1C) and aortic root
1.7-fold increase, p  0.018) (Fig. 1D), 2 highly athero-
enic vascular beds in this animal model. In contrast,
19ARF inactivation did not affect plaque size in the less
therogenic thoracic aorta (Fig. 1C) and ascending aorta
Fig. 1D).
We also examined the consequences of inactivating
19ARF on plaque composition. Analysis of the aortic root
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neointimal) content of Mac3-immunoreactive macro-
hages, SM -actin–immunoreactive VSMCs and colla-
en between apoE/p19/ and apoE/ mice (Fig. 2).
ikewise, lesion cellularity in the aortic root was similar
n both groups (apoE/: 6.21  1.02 cells/mm2, n  11;
poE/p19/: 6.07  1.13 cells/mm2, n  10).
ffects of p19ARF inactivation on cell proliferation and
poptosis in atherosclerotic lesions and macrophage and
SMC cultures. We next sought to investigate the
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hown). In contrast, apoE/p19/ VSMCs entered
arlier into the S and G2/M phases of the cell cycle
ompared with apoE/ controls, as determined by flow
ytometric analysis of starvation-synchronized cultures
hat were restimulated with serum (Fig. 3B). These
tudies demonstrated a significantly higher percentage
f cells in G1/G0 in apoE/ versus apoE/p19/
SMCs at all time points analyzed, and significantly higher
ercentages of cells in S (16 and 24 h) and G2/M (8, 16, and
4 h) in apoE/p19/ versus apoE/ cultures. More-
ver, differences in the percentages of apoE/ cells in
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Cross-sections from the aortic root (A) and from the ascending aorta (B) were sta
mal content of macrophages, vascular smooth muscle cells (VSMCs), and collagen
area occupied by atheroma. The photomicrographs (50 magnification) show repr
by the Student t test. apoE  apolipoprotein E.1/G0, S, and G2/M phases only reached statistical sig- tificance after 24 h of serum restimulation compared with
h (p  0.0001). However, in apoE/p19/ VSMCs,
ifferences in G1/G0, S, and G2/M phases reached statis-
ical significance at 8, 16, and 24 h after serum restimulation
ompared to 0 h (8 h vs. 0 h and 16 h vs. 0 h: p 0.05; 24 h
s. 0 h: p  0.0001). Taken together, these findings suggest
hat serum-restimulated apoE/p19/ VSMCs re-enter
he cell cycle faster than apoE/ cells.
Despite the increased proliferative capacity of cultured
SMC lacking p19ARF, cell proliferation was similar in aortic
oot cross-sections from apoE/ and apoE/p19/ mice fed
he atherogenic diet for 9 weeks (Fig. 3C), as estimated by
apoE-/-p19-/- (n = 10)
20
OOT
p=0.45
%
 n
eo
in
tim
al
co
lla
ge
n
co
nt
en
t p=0.97
 AORTA
20
%
 n
eo
in
tim
al
co
lla
ge
n
co
nt
en
t p=0.6=0.1
fect Atherosclerotic Plaque Composition
ith anti-Mac3, anti-SM -actin, and Masson’s trichrome to quantify the neointi-
ectively. Quantification is shown as percentage of stained area relative to the
tive images of aortic root sections. Differences between groups were evaluatedC R
NG
p
ot Af
ined w
, resp
esentahe neointimal content of Ki67-positive cells. Likewise,
q
t
d
K
K
p
a
w
e
p
a
(
(
S
c
2263JACC Vol. 55, No. 20, 2010 Gonza´lez-Navarro et al.
May 18, 2010:2258–68 p19ARF Deficiency Aggravates Atherosclerosisuantification of neointimal Ki67-immunoreactive cells in
he ascending aorta did not reveal statistically significant
ifferences between both groups (apoE/: 52.9  5.6%
i67-positive cells, n  11; apoE/p19/: 46.9  4.8%
i67-positive cells, n  10, p  0.05). Neointimal cell
roliferation was also undistinguishable in apoE/ and
poE/p19/ mice fed the atherogenic diet for 4 weeks,
A   
iv
e
BMDM
p=0.91
25
B
rd
U
-p
os
iti
ce
lls
 (%
)
B
aapoE-/-
p19-/-
apoE-/-
VSMC
E / ( 3)
f c
el
ls
apo - - n = 
apoE-/-p19-/- (n = 5)
G1/G0-phase
* ****
Pe
rc
en
ta
ge
 o
f
25
50
75
*
25
7- %
)
C
t (hours)
p=0.29
8 16 240 0
oi
nt
im
al
 K
i6
7
iti
ve
 c
el
ls
 (% 30
N
eo
po
si
(n = 10)
apoE-/-
p19-/-(n = 11)
apoE-/-
Figure 3 Effects of p19ARF Inactivation on Cell Proliferation in
Statistical analysis was carried out using the Student t test in A and C and 2-way
detected by immunofluorescence to visualize bromodeoxyuridine (BrdU) incorporati
sus total cells and are the average of 4 independent experiments (3 pools of BMD
cation. (B) Vascular smooth muscle cell (VSMC) cell-cycle profile analysis by flow c
restimulated for the indicated times. The results are representative of 2 independ
apoE/p19/ VSMCs at each time point of serum restimulation are shown. In
phases only reached statistical significance after 24 h of serum restimulation com
G1/G0, S, and G2/M phases reached statistical significance at 8, 16, and 24 h a
24 h vs. 0 h: p  0.0001). (C) Aortic root cross-sections from mice fed atherogen
Images were captured at a magnification of 1,000 and quantification is shown as pehich exhibited incipient lesions (Online Fig. S1). Inter- estingly, the mRNA level of the cytostatic gene product
16INK4a was markedly increased in the aortic arch of
poE/p19/ mice fed the atherogenic diet for 4 weeks
17-fold increase vs. apoE/, p  0.05) and 9 weeks
23-fold increase vs. apoE/, p  0.0005) (Online Fig.
2A). This compensatory mechanism does not occur in
ultured VSMCs, since no statistically significant differ-
Hoechst
anti-BrdU
-/- apoE-/-p19-/-
p<0.0001 apoE-/-p19-/-
p<0.0008
p<0.04
vs. apoE-/-
(same time-point)
G2/M-phasehase
*
20
*
******
8 16 24016 24
apoE-/-p19-/--/-
ns and in Cultured Macrophages and VSMCs
in B. (A) Proliferating bone marrow-derived macrophages (BMDMs) were
ng anti-BrdU antibody. Results are shown as a percentage of BrdU positive ver-
experiment per genotype). Representative images are shown at 200 magnifi-
try. Cells were synchronized at G0/G1 phase by serum deprivation for 72 h and
periments. For simplicity, only statistical comparisons between apoE/ and
/ cultures, differences in the percentage of cells in G1/G0, S, and G2/M
to 0 h (p  0.0001). However, in apoE/p19/ VSMCs, differences in
rum restimulation compared to 0 h (8 h vs. 0 h and 16 h vs. 0 h: p  0.05;
for 9 weeks were stained with anti-Ki67 antibody to quantify cell proliferation.
ge of positive cells within the neointimal lesion. apoE  apolipoprotein E.poE
*
**
***
S-p
8
apoE
Lesio
ANOVA
on usi
M per
ytome
ent ex
apoE
pared
fter se
ic diet
rcentances in p16INK4a expression were detected when comparing
c
t
c
l
t
d
l
r
r
d
(
t
f
w
a
m
d
i
(
2264 Gonza´lez-Navarro et al. JACC Vol. 55, No. 20, 2010
p19ARF Deficiency Aggravates Atherosclerosis May 18, 2010:2258–68ells of both genotypes (Online Fig. S2B). We also observed
hat expression of p15INK4b in both aortic tissue and
ultured VSMCs is unaffected by disrupting p19ARF (On-
ine Fig. S2). Thus, p19ARF ablation increases significantly
he proliferative capacity of cultured VSMCs in vitro but
oes not affect neointimal cell proliferation at different
esional stages, possibly due to a compensatory up-
egulation of p16INK4a in aortic tissue.
To assess the role of p19ARF in plaque’s apoptosis, aortic
oot cross-sections were examined using the terminal
a
TUN
50
%
 T
U
N
EL
 +
M
ac
3 
+ 
ce
lls
A   
N
eo
in
tim
al
TU
N
EL
 +
ce
lls
(%
)
p< 0.0055
3
apoE-/-
p19-/-
(n = 9)
apoE-/-
(n = 8)
5
%
 T
U
N
EL
 +
SM
α
-a
ct
in
+
ce
lls
B   
150
p<0.005
N
eo
in
tim
al
TU
N
EL
 +
ce
lls
/ m
m
2
p=0.67
p=0.31
apoE-/-
p19-/-
(n = 9)
apoE-/-
(n = 8)
Figure 4 p19ARF Inactivation in apoE/ Mice Reduces Apopto
Aortic root cross-sections from fat-fed mice were analyzed. (A) Apoptosis quantifie
(TUNEL)-positive cells within the lesion and as TUNEL-positive cells per square mil
TUNEL/SM -actin (bottom) to identify apoptotic macrophages and vascular smoo
cells doubly positive for TUNEL and Mac3 or SM -actin relative to the total numbe
tive images at a magnification of 1,000. Statistical analysis was carried out usineoxynucleotidyl transferase dUTP nick-end labeling
TUNEL) method. We found a significant reduction in
he percentage of TUNEL-positive cells in atheromas
rom apoE/p19/ compared with apoE/ mice, both
hen quantified as percentage TUNEL-positive cells and
s absolute number of TUNEL-positive cells per square
illimeter of lesion (Fig. 4A). We also carried out
ouble-staining experiments to identify apoptotic neo-
ntimal macrophages (TUNEL/Mac3) and VSMCs
TUNEL/SM -actin). In both groups of mice, 70%
apoE-/-p19-/--/-
EL + Mac3 - TUNEL + Mac3 +
SM α-actin - TUNEL + SM α-actin +
apoE-/-p19-/-E-/-
Atherosclerotic Lesions
ercentage of terminal deoxynucleotidyl transferase dUTP nick-end labeling
rs of lesion. (B) Sections were doubly stained with TUNEL/Mac3 (top) or
scle cells (VSMCs), respectively. The results are represented as percentage of
UNEL-positive cells within the atheroma. The photomicrographs show representa-
Mann-Whitney U test. apoE  apolipoprotein E.poE
TUN
EL + 
apo
sis in
d as p
limete
th mu
r of T
g the
a
m
e
T
n
o
m
a
p
d
p
B
fl
2265JACC Vol. 55, No. 20, 2010 Gonza´lez-Navarro et al.
May 18, 2010:2258–68 p19ARF Deficiency Aggravates Atherosclerosisnd 4% of apoptotic cells in atherosclerotic lesions were
acrophages and VSMCs, respectively (Fig. 4B, results
xpressed as percentage of cells doubly positive for
UNEL and Mac3 or SM-actin relative to the total
umber of TUNEL-positive cells within the atheroma).
To further investigate the role of p19ARF in the control
f macrophage and VSMC apoptosis, we prepared pri-
lls
 (%
)
A   
30
p=0.0001
p<0.04BMDM
Su
b-
G
0 
ce
l
Basal UV GSNO FC
apoE /
p<0.025
p=0.37
- -
apoE-/-p19-/-
Basal UV GSNO FC
B
VSMC
Propidium iodide
Su
b-
G
0 
ce
lls
 (%
)
p<0.0001
p<0.007
25
50
p=0.83
Basal UV GSNO
apoE-/-
apoE-/-p19-/-
ONSGVUlasaB
Propidium iodide
Figure 5 p19ARF Inactivation Reduces Apoptosis in Primary BM
Apoptotic cells were identified by flow cytometry as the sub-G0 population after propid
methods represent the average of 2 independent experiments each performed in tripl
of fluorescent signal; see the Methods section). (A) bone marrow–derived macrophag
vested after 24 h), or incubated with 2 mM S-nitrosoglutathione (GSNO) (2 mM) or fre
experiments (apoE/: 3 pools of cells per experiment; apoE/p19/: 4 pools of c
irradiated with UV light (120 J/m2 and harvested after 48 h), or incubated with 2 mMary cultures of BMDMs and VSMCs from apoE/
nd apoE/p19/ mice and exposed them to several
roapoptotic stimuli, including UV, the nitric oxide
onor GSNO, and free cholesterol. As shown in Fig. 5A,
19ARF deficiency significantly reduced apoptosis in
MDMs treated with all 3 stimuli, as measured using 2
ow cytometry approaches (propidium iodide staining to
el
ls
 (%
) p < 0.03
30
BMDM
po
si
tiv
e 
ce
p < 0.0003
Basal UV GSNO FC
p=0.89 p=0.67
Basal UV GSNO FC
Cleaved caspase-3
VSMC
po
si
tiv
e 
ce
lls
 (%
)
p<0.0003
p<0.0001
25
50
p=0.70
Basal UV GSNO
Cleaved caspase-3
ONSGVUlasaB
and VSMC Cultures
ide staining or as cleaved–caspase-3 immunoreactive cells. Results using both
epresentative plots are shown below the graphs (y-axis: cell counts; x-axis: intensity
DMs) were untreated (basal), irradiated with ultraviolet (UV) light (80 J/m2 and har-
sterol (FC) (100 g/ml) for 24 h. Results represent the average of 3 independent
r experiment). (B) Vascular smooth muscle cells (VSMCs) were untreated (basal),
for 48 h. Statistical analysis was carried out using 2-way ANOVA.sp
as
e-
3 
C
le
av
ed
 c
a
C
le
av
ed
 c
as
pa
se
-3
 
DM
ium iod
icate. R
es (BM
e chole
ells pe
GSNO
i
s
V
a
a
v
V
T
t
l
B
D
T
o
e
o
s
h
t
m
p
b
s
a
a
c
p
a
b
a
a
s
(
h
b
r
T
p
a
d
i
r
c
t
(
s
9
o
a
t
c
T
c
m
p
b
p
Q
d
V
w
(
c
i
p
d
c
(
a
9
c
l
w
9
t
c
a
a
b
i
d
m
t
p
a
p
p
e
t
a
u
p
a
h
i
t
f
c
c
i
c
p
g
t
t
2266 Gonza´lez-Navarro et al. JACC Vol. 55, No. 20, 2010
p19ARF Deficiency Aggravates Atherosclerosis May 18, 2010:2258–68dentify sub-G0 cells and cleaved caspase-3 immuno-
taining). Similarly, p19ARF inactivation in apoE/
SMCs significantly limited apoptosis induced by UV
nd GSNO (Fig. 5B). Free cholesterol, which induced
poptosis in macrophages (Fig. 5A) (31), failed to pro-
oke apoptotic cell death in apoE/ and apoE/p19/
SMCs compared with untreated controls (not shown).
his lack of apoptotic response in free-cholesterol–
reated VSMCs correlated with the absence of intracel-
ular cholesterol vesicles, which were abundant in
MDMs exposed to this lipid (not shown).
iscussion
he major finding of the present study is that deficiency
f the p19ARF protein, one of the tumor suppressors
ncoded by the CDKN2A gene, accelerates atheroma devel-
pment in the atherosclerosis-prone aortic arch (en face
tudy) and aortic root (analyzed in tissue cross-sections) of
ypercholesterolemic apoE-null mice (Fig. 1). This pheno-
ype is not observed in less atherogenic regions of the same
ice (e.g., ascending and thoracic aorta), suggesting that
19ARF is not involved in the initiation of atherosclerosis
ut regulates atheroma development in more advanced
tages of the disease. Notably, apoptosis is reduced in
poE/p19/ compared with apoE/ plaques (Fig. 4),
nd p19ARF inactivation attenuates apoptosis in primary
ultures of macrophages and VSMCs exposed to different
ro-apoptotic stimuli (Fig. 5). Of note, recent genome-wide
ssociation studies in humans have reported an association
etween several SNPs in a region of chromosome 9p21
djacent to the CDKN2A/CDKN2B loci and the risk of
therosclerotic diseases (19–25). Moreover, it has been
hown that expression of transcripts encoded by these genes
e.g., p15INK4b, p16INK4a, ANRIL, and p14ARF, the human
omolog of murine p19ARF) is lower in purified peripheral
lood T cells of individuals homozygous for the atheroscle-
osis risk G allele of one of these SNPs (rs10757278) (26).
hus, our findings demonstrating a direct link between
19ARF, plaque apoptosis, and atherosclerosis burden in
poE/ mice suggest a molecular mechanism by which
iminished expression of ARF associated to genetic variants
n the CDKN2A gene may increase the risk of atheroscle-
osis by limiting plaque apoptosis.
Because p19ARF expression has been shown to promote
ellular senescence to avoid proliferation of aberrant, poten-
ially hazardous cells in some pathophysiological settings
e.g., aging and cancer) (10,11), we evaluated aortic cell
enescence in apoE/ (n  10) and apoE/p19/ (n 
) mice fed the atherogenic diet for 9 weeks. In both groups
f mice, we found essentially negligible senescence-
ssociated beta-galactosidase staining in cryosections
hrough the aortic valves, with some scarce, faintly positive
ells within the neighboring cardiac tissue (data not shown).
hus, reduced aortic cell senescence does not appear to wontribute to increased atherosclerosis in apoE/p19/
ice. We also investigated the consequences of disrupting
19ARF on the expression of the proto-oncogen Myc, since
oth proteins have been shown to directly interact, and
14ARF down-regulates Myc-activated transcription (32).
uantitative polymerase chain reaction (qPCR) analysis
emonstrated increased c-myc expression in mouse aortic
SMCs lacking p19ARF (Online Fig. S3A), which, together
ith the lack of compensatory up-regulation of p16INK4a
Online Fig. S2B), might contribute to the higher proliferative
apacity of cultured apoE/p19/ VSMCs (Fig. 3B). Sim-
larly, p19ARF inactivation augmented significantly c-myc ex-
ression in the aortic arch of apoE/mice fed the atherogenic
iet for 4 weeks (Online Fig. S3B), but this response did not
orrelate with changes in cell proliferation within the atheroma
Online Fig. S1). Moreover, c-myc expression was similar in
poE/ and apoE/p19/ mice fed an atherogenic diet for
weeks (Online Fig. S3B). Thus, the effect of p19ARF on
-myc expression in the aortic arch appears to depend on
esional stage (e.g., increased expression in small lesions at 4
eeks of fat diet and no effect in more advanced lesions after
weeks of diet). Hence, further research appears warranted
o elucidate the complex functional connections between
-myc, p19ARF, and proliferation at different stages of
therosclerosis.
Both cell proliferation and apoptosis are prevalent in
therosclerotic lesions (5–8). Therefore, changes in the
alance between hyperplastic growth and apoptosis of neo-
ntimal cells are of major importance in atherosclerosis
evelopment. Indeed, atheroma progression is affected in
ice with altered expression of several tumor suppressors
hat modulate cell proliferation and apoptosis. Unlike
21Cip1, whose genetic ablation unexpectedly protects from
therosclerosis in apoE-null mice (33,34), the absence of
53 (35–38), p27Kip1 (39,40), and retinoblastoma (41)
roteins aggravates atherosclerosis in different murine mod-
ls (apoE-null, LDL receptor-null, and apoE*3-Leiden
ransgenic mice). Excessive proliferation of macrophages
nd VSMCs has been suggested as a mechanism contrib-
ting to the acceleration of atherosclerosis in mice lacking
27Kip1, retinoblastoma, and p53. We also found increased
therosclerosis burden in apoE-null mice lacking p19ARF;
owever, this phenotype did not appear to correlate with
ncreased cell proliferation within the plaque, possibly due
o a marked up-regulation in aortic tissue of the INK4
amily growth suppressor p16INK4a (Online Fig. S2A). This
ompensatory mechanism does not appear to occur in
ultured VSMCs since apoE/p19/ VSMCs exhibited
ncreased proliferative capacity compared with apoE/
ontrols, and no statistically significant differences in
16INK4a expression were detected between cells of both
enotypes (Online Fig. S2B).
In agreement with the well-established proapoptotic func-
ion of p19ARF, our in vivo studies reveal a 2-fold reduction in
he content of apoptotic cells in apoE/p19/ compared
ith apoE/ plaques (Fig. 4A). Notably, we find that the
r
a
m
t
e
i
t
a
t
a
s
i
p
d
p
a
a
a
a
s
e
r
o
a
a
m
a
p
a
C
G
a
a
n
u
i
m
n
i
f
n
t
i
w
p
v
a
o
o
C
A
R
S
c
c
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2267JACC Vol. 55, No. 20, 2010 Gonza´lez-Navarro et al.
May 18, 2010:2258–68 p19ARF Deficiency Aggravates Atherosclerosiselative proportion of apoptotic neointimal macrophages
nd VSMCs is unchanged in apoE/p19/ and apoE/
ice (70% and 4%, respectively) (Fig. 4B), suggesting
hat lack of p19ARF protects from apoptosis to the same
xtent in both cell types. Future studies are required to
nvestigate whether apoptosis of other cell types present in
he atheroma might be differentially affected by p19ARF
blation. Consistent with our in vivo results, p19ARF inac-
ivation also reduces apoptosis by 30% to 57% in BMDMs
nd VSMCs cultures exposed to different proapoptotic
timuli (Fig. 5). The finding that GSNO-induced apoptosis
s attenuated in apoE/p19/ cells is in concordance with
revious studies demonstrating that efficient nitric oxide-
ependent macrophage apoptosis requires the activation of
19ARF (42).
Consistent with the possibility that decreased apoptosis is
mechanism by which p19ARF inactivation aggravates
theroma progression, a reduction in apoptotic cell death,
ccompanied or not by changes in cellular plaque prolifer-
tion, has been previously associated with increased athero-
clerosis in several genetically modified mouse models. For
xample, ablation of p53, a downstream target of p19ARF,
educes apoptosis and increases atheroma formation in some
f the models studied (37,38). Moreover, the unexpected
ggravation of atherosclerosis in apoE/ compared with
poE/p21/ mice also coincides with reduced neointi-
al apoptosis (33), in agreement with the reported anti-
poptotic role of p21Cip1 (43). However, decreased macro-
hage apoptosis might be beneficial in advanced stages of
therosclerosis by reducing the risk of plaque rupture (44).
onclusions
enetic inactivation of p19ARF in atherosclerosis-prone
poE-null mice limits apoptosis of neointimal macrophages
nd VSMCs, and worsens atherosclerosis without affecting
eointimal cell proliferation, possibly due to a compensatory
p-regulation of p16INK4a. These findings suggest that
nterventions aimed at increasing the expression of ARF
ay lessen plaque progression. Our results also support the
otion that decreased plaque apoptosis might contribute to
ncreased risk of atherosclerosis in individuals homozygous
or the G allele of rs10757278, who exhibit reduced levels of
ot only ARF, but also p15INK4b, p16INK4a, and ANRIL
ranscripts in blood-borne T cells (26). Thus, it will be of
nterest to generate additional mouse models to determine
hether atherosclerosis is also aggravated upon deficiency of
15INK4b, p16INK4a, and ANRIL, and if combined inacti-
ation of 2 or more CDKN2A/CDKN2B genes potentiates
therosclerosis more than does single-gene ablation. More-
ver, further studies are warranted to ascertain whether
ther atherosclerosis risk variants near the CDKN2A/
DKN2B loci also lead to diminished expression of INK4/
RF transcripts.eprint requests and correspondence: Dr. Vicente Andrés,
panish National Cardiovascular Research Center (CNIC), Mel-
hor Ferna´ndez Almagro 3, 28029 Madrid, Spain. E-mail: vandres@
nic.es.
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APPENDIX
or an expanded Methods section and
upplementary figures, please see the online version of this article.
